Savings Associated With "Skinny Label" Biosimilars
JAMA Intern Med
.
2023 Jan 1;183(1):84.
doi: 10.1001/jamainternmed.2022.5418.
Authors
Eric Ward
1
2
,
Robert Steinbrook
3
Affiliations
1
Department of Medicine, University of California, San Francisco.
2
Editorial Fellow, JAMA Internal Medicine.
3
Editor at Large and Online Editor, JAMA Internal Medicine.
PMID:
36441538
DOI:
10.1001/jamainternmed.2022.5418
No abstract available
Publication types
Editorial
Comment
MeSH terms
Biosimilar Pharmaceuticals*
Cost Savings
Drug Approval
Humans
Income
Substances
Biosimilar Pharmaceuticals